Philips Integrates AI Tools in Cardiovascular Systems

Royal Philips has released its next-generation AI-enabled cardiovascular ultrasound platform to help speed up cardiac ultrasound analysis and reduce the burden on echocardiography labs. The new applications are FDA 510(k) cleared and are integrated into the company’s EPIQ CVx and Affiniti CVx ultrasound systems. 
 
The AI application helps improve the quality and reproducibility of cardiac imaging, enhances operator and departmental efficiency, and advances diagnosis solutions, automating measurements and speeding workflows to increase productivity. 
 
In operation with software solutions from DiA Imaging Analysis, the AI can automate how users interpret ultrasound images, so clinicians with varying levels of ultrasound experience can automatically analyze images with increased speed, efficiency, and accuracy in real-time.
 
“As clinical cases get more complex and patient volumes increase, we read hundreds of echocardiography exams daily with thousands of data points,” said Roberto Lang, MD, Director of the Noninvasive Cardiac Imaging Lab, University of Chicago Medicine, USA. “With the integration of AI into echocardiography solutions, we can now automate some of the steps to support clinicians’ decision-making, allowing them to detect, diagnose, and monitor various cardiac conditions with greater confidence and efficiency in seconds.”
 
Lang and other clinicians will share the results of a new scientific abstract at the American Society of Echocardiography from June 14-16. 
 
The scientific abstract will demonstrate how AI algorithms co-developed with Philips provide highly accurate detection of regional wall motion abnormalities (RWMA) on echocardiography. Automated machine learning-based assessment of RWMA has the potential to improve the efficiency of all readers.
 
In addition to integrating the latest advanced AI features into the company’s cardiovascular ultrasound systems, Philips’ new mini ultrasound transducer X11 4t is fully compatible with the EPIQ CVx and Affiniti CVx systems. The innovative transducer allows interventional cardiologists to provide enhanced care to a wider range of patients, including pediatric patients as small as 5kg in weight.
 
“By harnessing the power of AI into our echocardiography solutions, we empower clinicians with enhanced diagnostic capabilities, to ultimately improve patient care and outcomes in the management of coronary and valvular disease, while enhancing overall efficiency in cardiac practice,” said David Handler, VP and Business Leader for Global Cardiovascular Ultrasound at Philips. “For patients, this means consistent image interpretation which can lead to fewer re-scans, shorter and more effective interventional procedures, and potentially faster recovery times.”